Asad Haider
Stock Analyst at Goldman Sachs
(2.91)
# 1,441
Out of 5,149 analysts
15
Total ratings
85.71%
Success rate
21.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Upgrades: Buy | $115 → $142 | $107.48 | +32.12% | 2 | Jan 16, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $213 → $240 | $248.56 | -3.44% | 3 | Dec 19, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Neutral | $30 → $37 | $32.83 | +12.70% | 2 | Dec 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $57 | $62.34 | -8.57% | 2 | Dec 2, 2025 | |
| INVA Innoviva | Initiates: Sell | $17 | $22.83 | -25.54% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $47.47 | -11.52% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $61.98 | -38.69% | 1 | Sep 12, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $1,017.97 | -12.77% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $234.26 | -17.19% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $27.26 | -8.29% | 1 | Apr 8, 2025 |
BioNTech SE
Jan 16, 2026
Upgrades: Buy
Price Target: $115 → $142
Current: $107.48
Upside: +32.12%
Johnson & Johnson
Dec 19, 2025
Maintains: Buy
Price Target: $213 → $240
Current: $248.56
Upside: -3.44%
NewAmsterdam Pharma Company
Dec 2, 2025
Maintains: Neutral
Price Target: $30 → $37
Current: $32.83
Upside: +12.70%
Bristol-Myers Squibb Company
Dec 2, 2025
Maintains: Neutral
Price Target: $51 → $57
Current: $62.34
Upside: -8.57%
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $22.83
Upside: -25.54%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $47.47
Upside: -11.52%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $61.98
Upside: -38.69%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $1,017.97
Upside: -12.77%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $234.26
Upside: -17.19%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $27.26
Upside: -8.29%